Apollo Hospitals Enterprise Earnings Call Transcripts
Fiscal Year 2026
-
Q3 FY26 saw 17% year-over-year consolidated revenue growth and 35% PAT growth, with all business segments delivering strong results. New hospital capacity is being added in phases, and digital business break-even is now expected in Q1 FY27 due to insurance revenue timing.
-
Q2 FY26 saw 13% revenue growth and 15% EBITDA growth year-on-year, with strong performance across all business segments and robust margins. Six new hospitals are set to be commissioned by next fiscal, with digital and pharmacy businesses on track for break-even and further margin expansion expected.
-
Q1 FY 2026 delivered 15% revenue growth and 42% PAT growth, with strong performance across all segments. Digital business is nearing breakeven, hospital expansion is on track, and the pharmacy demerger with Keimed is expected to drive further scale and margin gains.
Fiscal Year 2025
-
Consolidated revenue grew 14% YoY to INR 21,794 crore in FY 2025, with double-digit growth across all verticals and strong EBITDA margin performance. Major expansion plans are underway, digital and pharmacy businesses are targeting 20-30% annual growth, and the company remains confident in sustaining its growth trajectory despite headwinds from Bangladesh patient flows.
-
Q3 FY25 saw 14% revenue and 52% PAT growth, with robust margins and strong specialty performance. Digital and pharmacy businesses improved profitability, and new facilities plus insurance offerings are set to drive future growth.
-
Q2 FY25 saw 15% revenue growth and 63% PAT growth, with strong performance across all segments and Apollo HealthCo's first profit. Expansion plans remain on track, with robust cash flows and a focus on sustainable, margin-accretive growth.
-
Strong year-on-year revenue and profit growth driven by higher volumes, insurance penetration, and digital expansion. Margin improvement expected as new hospitals and digital initiatives scale, with continued focus on cost optimization and operational leverage.